Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5658417 | Gastroenterology | 2017 | 48 Pages |
Abstract
In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Bruce E. Sands, Jingjing Chen, Brian G. Feagan, Mark Penney, William A. Rees, Silvio Danese, Peter D.R. Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra, Jing Li, Paul Klekotka, Chris Morehouse, Erik Pulkstenis, Jörn Drappa, René van der Merwe,